Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

About MaverickNY

Here are my most recent posts

Posts by MaverickNY

A couple of years ago I was listening to an early stage drug hunter expert talk about how they were going to do things differently in building their oncology pipeline.

Simulations galore!

At the time, they had no official targets announced and much of the noise and attention was on the filling of seats on the Board or leading positions in the company, so very early days indeed.

The following year heralded an IPO, dosing of the initial patient in their inaugural clinical trial and just a few months later, their very first licensing deal and collaboration with a large Pharma company, so clearly a young biotech company going places.

What’s happened since and what so different or special about their approach to cancer drug development?

It turns out there were some surprises in store and some very cool science behind it…

BSB subscribers can learn more about our latest interview in the AI/deep learning niche – you can read all about it by logging in or click to access our ongoing oncology coverage.

This content is restricted to subscribers

It’s time to switch gears and talk about neoantigens again… we’ve been covering this niche since 2015, as you can see from the relevant magazine page.

Aside from today’s expert interview, there will be an important update coming at ESMO in the Fall so this is a good time to set the scene ahead of time.

In our latest discussion, we cover some of the AI/deep learning aspects of the technological developments with a view to how they connect with the clinical challenges and progress since they don’t obviously exist in isolation.

As always there are important lessons and learnings along the way, such is the roller coaster of R&D, especially in oncology…

BSB subscribers can learn more about our latest interview on how deep learning can be applied to the neoantigen niche – you can read all about it by logging in or click to access our ongoing oncology coverage.

This content is restricted to subscribers

As we continue our journey to learn more about how companies are exploiting cool new technologies around artificial intelligence, machine learning and deep learning, this time we explore some concepts around RNA therapies and find out how a biotech is making strides in this niche.

Imagine being able to analyse massive biological datasets to derive novel targets and therapeutics?

The open star cluster NGC 330 Source: NASA

Perhaps one of the more refreshing aspects which has struck me from the AI/ML niche so far is how eager, dynamic, and enthusiastic the CEOs have been to talk about what they are doing, why it’s exciting, what challenges need to be addressed, and where they are planning to go.

Today’s CEO interview is another great example of this genre.

While their current pipeline examples are non-oncology focused, if there are improvements in delivery technology then they may have future applications in cancer research for them too…

BSB subscribers can learn more about our latest interview in the AI/deep learning niche – you can read all about it by logging in or click to access our ongoing oncology coverage.

This content is restricted to subscribers

What do Smarties and machine learning have in common?

It’s a dull, wet, and gloomy day here in the south east, as if the Gods have decided to channel a typical English summer across the pond, so rather than talk about shadows in the rain there’s a much more cheerful and colourful topic to discuss.

In our latest expert interview on the topic of AI and deep learning, we turn to a dynamic CEO with a different approach and a clear vision.

Much of this space has focused on the issues around training and validation sets as well as the inherent challenge with bias being projected where is isn’t wanted or needed.

What if… we could ask a machine to tell us what it sees instead?

A word of warning – this has absolutely nothing to do with IBM Watson – and everything to do with biology and drug development!

BSB subscribers can learn more about our latest interview in the AI/deep learning niche – you can read all about it by logging in or click to access our ongoing oncology analysis.

This content is restricted to subscribers

It’s time to switch horses and take another look at the evolving bispecific antibody niche with a look at a particularly promising T cell engager in early clinical development, which might offer a few surprises.

We have seen these agents evolve in both hematologic malignancies as well as solid tumours, with a common challenge being CRS events.

What if this side effect could be made more manageable, enabling the agent to do its job on a dual front, namely reinvigorating T cells and reducing some of the hostile immunosuppression dampening down the immune responses?

How about as a potential partner for CAR-T cells to help improve expansion kinetics or in combination with checkpoint blockade so they could work more effectively?

It turns out all this can be done, perhaps in an unconventional and creative fashion…

BSB subscribers can learn more about our latest look at the T cell engager niche – you can log-in or click to access our ongoing oncology coverage.

This content is restricted to subscribers

Source: TripAdvisor

Over the last couple of years it has taken us until the end of July to rollout all of our coverage of AACR and ASCO, since data often co-mingles across the two key conferences… and this year is no exception to the rule.

Here we digest an early allcomers trial and point out some red and green flags to watch out for as we review some of the highlights in terms of what can be learned and what’s missing, but would be useful to know.

The short answer is there is quite a bit to discuss on both fronts…

 

BSB subscribers can learn more about our latest look at the TIGIT niche – you can log-in or click to access our ongoing oncology coverage.

This content is restricted to subscribers

Degron (red)  Credit: Dmeyer314 via wikipedia

One of the emerging hot areas in cancer research these days is the field of protein degradation, which finally seems to have come of age.

This also means plenty of opportunities to discuss new developments as they evolve.

So what’s new and why are the latest updates important?

BSB subscribers can read more on our latest look at targeted protein degradation related topics – you can log-in or click to access our ongoing oncology coverage.

This content is restricted to subscribers

In the second post of the day on overcoming immunosuppression and a hostile tumour microenvironment, we take an extended look at the TIGIT and adenosine pathways through the lens of a company active in both of these niches.

Karl the Fog in San Francisco

What are they doing and, importantly, why are they taking a particular approach?

Where might they also be going in the future?

In our latest expert interview we offer not one, but two, biotech executives from the context of the science and biology driving their commercial strategy.

With the latest announcement yesterday that their key phase 2 trial will continue and data to be presented at an updated medical meeting, there’s a lot to learn and some key pointers to think about.

BSB subscribers can read more on our latest look at a clinical stage biotech company active in the cancer immunosuppression space – you can log-in or click to access our ongoing oncology coverage.

This content is restricted to subscribers

It’s time to talk about new developments in immunosuppression and some of the different ways in which companies are tackling the hostile tumour microenvironment.

Obviously there are many potential culprits from neutrophils, macrophages, myeloid derived suppressor cells (MDSCs), adenosine, Siglec–15, and TGFβ to mention a few. There are others to consider as well, as we discuss with our latest experts in the hotseat.

Over the next couple of posts we will be highlighting different pipeline agents, along with in-depth expert interviews to explore some intriguing early or emerging approaches. Some are in preclinical getting ready to enter the clinic, while others are already being evaluated in phase 1/2 studies.

In this example of the genre, we had fun catching up on a biotech we first talked to a couple of years ago about their fledgling pipeline. How is doing now and what are they up to?

BSB subscribers can read more on our latest look at a clinical stage biotech company active in the cancer immunosuppression space – you can log-in or click to access our ongoing oncology coverage.

This content is restricted to subscribers

Lugano is such a glorious place to hold a cancer meeting!

You can tell how much fondness attendees and presenters have for a meeting location when many start off their talk with a shot of the scenery and remember fond times of past conferences.

Lugano and the International Conference on Malignant Lymphoma (iCML) – held every two years in odd numbered ones – is clearly one such event.

It is here where we learn about the broader context in terms of how various phase 3 trials truly fit in the landscape and whether or not they are practice changing, what the skinny is on a raft of new products in a given category from practitioners in the trials, including problematic or emerging side effects, or how agents might be more effective in one particular subset but not another, and so on.

This year’s meeting is no different despite the virtual nature of the event.  After a couple of recent on-line meetings were a bust due to an inability to host the volume of attendees, one might be forgiven for being a tad nervous this one might go the same way – but these fears were not realised, I’m delighted to say!

Instead, we were treated to a very well organised event with a series of high quality talks and posters on a variety of lymphoma related issues, including rapid turnaround for the on-demand recordings the next day for any sessions one missed.

BSB subscribers can read more on our latest look at key hematologic developments relating to lymphomas  – you can log-in or click to access our ongoing oncology coverage.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!